Nomination Committee

The Nomination Committee Proposes Election of Mark Quick and Erik Haeffler as New Board Members of Nanologica AB (publ)

10 March, 2026

The nomination committee of Nanologica proposes to the Annual General Meeting on May 21 that Mark Quick and Erik Haeffler be elected as new members of the board of directors of Nanologica AB. Furthermore, Thomas Eldered is proposed as new chairman of the board. Mark Quick works as a Partner at Flerie AB having previously worked at Recipharm where he was Head of Corporate Development leading the M&A activities. Prior to that he held positions

Valberedningen föreslår nyval av Mark Quick och Erik Haeffler som styrelseledamöter i Nanologica AB (publ)

10 March, 2026

Valberedningen i Nanologica föreslår inför årsstämman den 21 maj att Mark Quick och Erik Haeffler väljs som nya styrelseledamöter i Nanologica AB. Vidare föreslås Thomas Eldered som ny ordförande. Mark Quick arbetar som partner på Flerie AB och kommer från en tidigare roll på Recipharm där han var chef för företagsutveckling och ledde M&A-aktiviteterna. Innan dess har Mark Quick innehaft positioner inom ICI, Medeva, Celltech och UCB i olika roller inom affärsutveckling och leveranskedja. Han

NANOLOGICAS VALBEREDNING UTSEDD INFÖR ÅRSSTÄMMAN 2026

14 October, 2025

I enlighet med gällande valberedningsinstruktion har styrelsens ordförande kontaktat Nanologicas tre röstmässigt största ägare eller ägargrupper per den 30 september 2025, som var och en har erbjudits att utse en representant att utgöra valberedning i Nanologica AB inför årsstämman 2026. Valberedningen inför Nanologica AB:s årsstämma 2026 utgörs därmed av följande tre ledamöter: Carl-Johan Spak (Flerie Invest AB) Niklas Sjöblom (Konstakademiens stiftelser) Kalle Olby (Vega Bianca AB) Valberedningen representerar tillsammans 53,0 procent av röstetalet för samtliga

NANOLOGICA ANNOUNCES NOMINATION COMMITTEE FOR THE ANNUAL GENERAL MEETING 2026

14 October, 2025

In accordance with the current nomination committee instructions, the chairman of the board has contacted Nanologica's three largest shareholders or owner groups in terms of voting rights as of September 30, 2025, each of whom has been offered to appoint a representative to constitute the nomination committee of Nanologica AB for the 2026 Annual General Meeting. The nomination committee for Nanologica AB's AGM 2026 thus consists of the following three members: Carl-Johan Spak (Flerie Invest

Nanologicas valberedning utsedd inför årsstämman 2025

11 November, 2024

I enlighet med gällande valberedningsinstruktion har styrelsens ordförande kontaktat Nanologicas tre röstmässigt största ägare eller ägargrupper per den 30 september 2024, som var och en har erbjudits att utse en representant att utgöra valberedning i Nanologica AB inför årsstämman 2025.I enlighet med gällande valberedningsinstruktion har styrelsens ordförande kontaktat Nanologicas tre röstmässigt största ägare eller ägargrupper per den 30 september 2024, som var och en har erbjudits att utse en representant att utgöra valberedning i Nanologica

Nanologica Announces Nomination Committee for the Annual General Meeting 2025

11 November, 2024

In accordance with the current nomination committee instructions, the chairman of the board has contacted Nanologica's three largest shareholders or owner groups in terms of voting rights as of September 30, 2024, each of whom has been offered to appoint a representative to constitute the nomination committee of Nanologica AB for the 2025 Annual General Meeting. As a result of changes in ownership in the company following the rights issue that ended on September 30,

About us

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica’s share (ticker NICA) has been listed on Nasdaq Stockholm’s main market since 2022.